Overview

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis